Research
Hormonal
Targeting de novo lipogenesis (DNL) via ACC inhibitors (e.g., GS-0976, MK-4074) significantly reduces hepatic steatosis and DNL in patients with NASH.
ACC inhibitors like GS-0976 are being tested to directly reduce liver fat production. In trials, 20mg daily for 12 weeks reduced liver fat by 29%, significantly better than placebo. This is a pharmacological option for those who may not achieve sufficient weight loss through lifestyle alone.
GoodSupportsHIGH confidence
GS-0976 decreased hepatic steatosis... median relative decreases in magnetic resonance imaging-estimated proton density fat fraction (MRI-PDFF) were greater in patients treated with 20 mg of ACC inhibitor GS-0976 for 12 weeks (decrease of 29%) than those given placebo (decrease of 8%; p = 0.002).
Why this rating
Supported by Phase 2 clinical trials showing significant reduction in liver fat.
Source
Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)
Xiaohan Xu et al. · Signal Transduction and Targeted Therapy · 2022
DOI 10.1038/s41392-022-01119-3
narrative_reviewCited 332×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Weight loss of 10% or more through lifestyle interventions (hypocaloric diet and exercise) is necessary to achieve regression of liver fibrosis in patients with NAFL/NASH.Good
- Mediterranean Diet (MD) is the recommended first-choice diet for NAFL/NASH patients, improving hepatic steatosis and visceral fat, though its efficacy in advanced NASH requires further investigation.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →